Economic impact of screening for bladder cancer using bladder tumor markers

A decision analysis

Robert S. Svatek, Arthur I Sagalowsky, Yair Lotan

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Purpose: The Food and Drug Administration recently approved the use of bladder markers such as BladderChek (NMP22; Matritech, Inc., Newton, MA) and UroVysion (Abbott Laboratories, Abbott Park, IL) for use in screening for bladder cancer. The purpose of this analysis was to assess the cost associated with implementing a widespread screening program using a noninvasive bladder tumor marker. Methods: Data for the accuracy of NMP22 in detecting bladder cancer was gathered from a comprehensive literature review. A decision tree analysis was constructed to evaluate the total cost of screening a low and high-risk population for bladder cancer using NMP22. Sensitivity analyses were conducted to evaluate the effect of relaxing the various assumptions in the model. Results: Application of the model to all men, regardless of the degree of risk, rendered a cost per cancer detected of $783,913, $269,028, and $139,305 for ages 50-59, 60-69, and 70-79 years, respectively. Screening only patients at high-risk for bladder cancer (annual incidence 6%) would yield a cost per cancer detected of $3,310. Incidence of cancer and marker specificity had the highest influence on cost per cancer detected. Conclusions: Application of NMP22 to the entire population would render an extremely high cost per cancer detected. However, application to an appropriate high-risk target population could achieve cost per cancer detected comparable to currently used screening programs for prostate, colon, and breast cancer. Further studies are needed to assess the accuracy of bladder tumor markers in detecting bladder cancer in a completely asymptomatic cohort.

Original languageEnglish (US)
Pages (from-to)338-343
Number of pages6
JournalUrologic Oncology: Seminars and Original Investigations
Volume24
Issue number4 SPEC. ISS.
DOIs
StatePublished - Jul 2006

Fingerprint

Decision Support Techniques
Tumor Biomarkers
Urinary Bladder Neoplasms
Economics
Costs and Cost Analysis
Neoplasms
Decision Trees
Health Services Needs and Demand
Incidence
United States Food and Drug Administration
Colonic Neoplasms
Population
Prostatic Neoplasms
Urinary Bladder
Breast Neoplasms
nuclear matrix protein 22

Keywords

  • Bladder cancer
  • Cost
  • Nuclear matrix protein 22
  • Screening
  • Urine biomarker

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Economic impact of screening for bladder cancer using bladder tumor markers : A decision analysis. / Svatek, Robert S.; Sagalowsky, Arthur I; Lotan, Yair.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 24, No. 4 SPEC. ISS., 07.2006, p. 338-343.

Research output: Contribution to journalArticle

@article{26e0b859e98e4a20b85db5b893ae5c0b,
title = "Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysis",
abstract = "Purpose: The Food and Drug Administration recently approved the use of bladder markers such as BladderChek (NMP22; Matritech, Inc., Newton, MA) and UroVysion (Abbott Laboratories, Abbott Park, IL) for use in screening for bladder cancer. The purpose of this analysis was to assess the cost associated with implementing a widespread screening program using a noninvasive bladder tumor marker. Methods: Data for the accuracy of NMP22 in detecting bladder cancer was gathered from a comprehensive literature review. A decision tree analysis was constructed to evaluate the total cost of screening a low and high-risk population for bladder cancer using NMP22. Sensitivity analyses were conducted to evaluate the effect of relaxing the various assumptions in the model. Results: Application of the model to all men, regardless of the degree of risk, rendered a cost per cancer detected of $783,913, $269,028, and $139,305 for ages 50-59, 60-69, and 70-79 years, respectively. Screening only patients at high-risk for bladder cancer (annual incidence 6{\%}) would yield a cost per cancer detected of $3,310. Incidence of cancer and marker specificity had the highest influence on cost per cancer detected. Conclusions: Application of NMP22 to the entire population would render an extremely high cost per cancer detected. However, application to an appropriate high-risk target population could achieve cost per cancer detected comparable to currently used screening programs for prostate, colon, and breast cancer. Further studies are needed to assess the accuracy of bladder tumor markers in detecting bladder cancer in a completely asymptomatic cohort.",
keywords = "Bladder cancer, Cost, Nuclear matrix protein 22, Screening, Urine biomarker",
author = "Svatek, {Robert S.} and Sagalowsky, {Arthur I} and Yair Lotan",
year = "2006",
month = "7",
doi = "10.1016/j.urolonc.2005.11.025",
language = "English (US)",
volume = "24",
pages = "338--343",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4 SPEC. ISS.",

}

TY - JOUR

T1 - Economic impact of screening for bladder cancer using bladder tumor markers

T2 - A decision analysis

AU - Svatek, Robert S.

AU - Sagalowsky, Arthur I

AU - Lotan, Yair

PY - 2006/7

Y1 - 2006/7

N2 - Purpose: The Food and Drug Administration recently approved the use of bladder markers such as BladderChek (NMP22; Matritech, Inc., Newton, MA) and UroVysion (Abbott Laboratories, Abbott Park, IL) for use in screening for bladder cancer. The purpose of this analysis was to assess the cost associated with implementing a widespread screening program using a noninvasive bladder tumor marker. Methods: Data for the accuracy of NMP22 in detecting bladder cancer was gathered from a comprehensive literature review. A decision tree analysis was constructed to evaluate the total cost of screening a low and high-risk population for bladder cancer using NMP22. Sensitivity analyses were conducted to evaluate the effect of relaxing the various assumptions in the model. Results: Application of the model to all men, regardless of the degree of risk, rendered a cost per cancer detected of $783,913, $269,028, and $139,305 for ages 50-59, 60-69, and 70-79 years, respectively. Screening only patients at high-risk for bladder cancer (annual incidence 6%) would yield a cost per cancer detected of $3,310. Incidence of cancer and marker specificity had the highest influence on cost per cancer detected. Conclusions: Application of NMP22 to the entire population would render an extremely high cost per cancer detected. However, application to an appropriate high-risk target population could achieve cost per cancer detected comparable to currently used screening programs for prostate, colon, and breast cancer. Further studies are needed to assess the accuracy of bladder tumor markers in detecting bladder cancer in a completely asymptomatic cohort.

AB - Purpose: The Food and Drug Administration recently approved the use of bladder markers such as BladderChek (NMP22; Matritech, Inc., Newton, MA) and UroVysion (Abbott Laboratories, Abbott Park, IL) for use in screening for bladder cancer. The purpose of this analysis was to assess the cost associated with implementing a widespread screening program using a noninvasive bladder tumor marker. Methods: Data for the accuracy of NMP22 in detecting bladder cancer was gathered from a comprehensive literature review. A decision tree analysis was constructed to evaluate the total cost of screening a low and high-risk population for bladder cancer using NMP22. Sensitivity analyses were conducted to evaluate the effect of relaxing the various assumptions in the model. Results: Application of the model to all men, regardless of the degree of risk, rendered a cost per cancer detected of $783,913, $269,028, and $139,305 for ages 50-59, 60-69, and 70-79 years, respectively. Screening only patients at high-risk for bladder cancer (annual incidence 6%) would yield a cost per cancer detected of $3,310. Incidence of cancer and marker specificity had the highest influence on cost per cancer detected. Conclusions: Application of NMP22 to the entire population would render an extremely high cost per cancer detected. However, application to an appropriate high-risk target population could achieve cost per cancer detected comparable to currently used screening programs for prostate, colon, and breast cancer. Further studies are needed to assess the accuracy of bladder tumor markers in detecting bladder cancer in a completely asymptomatic cohort.

KW - Bladder cancer

KW - Cost

KW - Nuclear matrix protein 22

KW - Screening

KW - Urine biomarker

UR - http://www.scopus.com/inward/record.url?scp=33745480734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745480734&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2005.11.025

DO - 10.1016/j.urolonc.2005.11.025

M3 - Article

VL - 24

SP - 338

EP - 343

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 4 SPEC. ISS.

ER -